{"nctId":"NCT02477618","briefTitle":"A Study With SAGE-547 for Super-Refractory Status Epilepticus","startDateStruct":{"date":"2015-06"},"conditions":["Super-Refractory Status Epilepticus"],"count":132,"armGroups":[{"label":"SAGE-547","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: SAGE-547"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SAGE-547","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects two (2) years of age and older\n* Subjects who have:\n\n  * Failed to respond to the administration of at least one first-line agent (e.g., benzodiazepine or other emergent initial anti-epileptic drug \\[AED\\] treatment), according to institution standard of care, and;\n  * Failed to respond to at least one second-line agent (e.g., phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control AED), according to institution standard of care, and;\n  * Not previously been administered a third-line agent but have been admitted to an intensive care unit with the intent of administering at least one third-line agent for at least 24 hours; or who have previously failed zero, one or more wean attempts from third-line agents and are now on continuous intravenous infusions of one or more third-line agent and in an EEG burst or seizure suppression pattern; or who have previously failed one or more wean attempts from third-line agents and are now either not on a continuous intravenous infusion of at least one third-line agent or are on a continuous intravenous infusion of one or more third-line agent but not in an EEG burst or seizure suppression pattern\n\nExclusion Criteria:\n\n* Subjects with SRSE due to anoxic/hypoxic encephalopathy with highly malignant/ malignant EEG features\n* Children (subjects aged less than 17 years) with an encephalopathy due to a rapidly progressing underlying neurological disorder\n* Subjects who have any of the following:\n\n  1. a glomerular filtration rate (GFR) low enough to warrant dialysis but for whatever reason, dialysis is not planned or non-continuous dialysis planned (that would not adequately remove Captisol®);\n  2. severe cardiogenic or vasodilatory shock requiring two or more pressors that is not related to third-line agent use;\n  3. fulminant hepatic failure;\n  4. no reasonable expectation of recovery (for instance, a likely outcome is persistent vegetative state) or life-expectancy, in the experience of the investigator, is less than 30 days.\n* Subjects who are being administered more than three third-line agents concomitantly or in whom the qualifying wean cannot be completed per protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥ 24 Hours Following the End of SAGE-547 or Placebo Infusion","description":"Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression electroencephalogram (EEG) pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \\>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Time Between the Primary Outcome Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression","description":"Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \\>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.500","spread":null},{"groupId":"OG001","value":"14.000","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Able to be Weaned Off All Third-line Agents Before the End of the First SAGE-547 or Placebo Infusion","description":"Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Time Between the Secondary Outcome Measure Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression","description":"Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.000","spread":null},{"groupId":"OG001","value":"15.000","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression Scale (CGI)","description":"The CGI scale was used to integrate several sources of information into a single rating of a participant's condition. The CGI was rated on a 7-point scale, from a minimum of 0 to a maximum of 7, where 0 = Not assessed; 1 = Normal, not at all ill; 2 = Borderline physically ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill participants. A negative change from baseline indicates improvement. A positive change from baseline indicates worsening. Here, study visits followed by \"R\" indicate the Open-label Treatment Period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"0.89"},{"groupId":"OG001","value":"5.9","spread":"1.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.42"},{"groupId":"OG001","value":"-0.6","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.36"},{"groupId":"OG001","value":"-0.5","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Number of Days After the End of the First Study Drug Infusion Without Status Epilepticus, Up to Visit 12","description":"Here, study visits followed by \"R\" indicate the Open-label Treatment Period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.05","spread":"6.738"},{"groupId":"OG001","value":"11.15","spread":"6.058"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.08","spread":"6.557"},{"groupId":"OG001","value":"9.23","spread":"6.345"}]}]}]},{"type":"SECONDARY","title":"Number of Days After the End of the First Study Drug Infusion Without Seizures (Convulsive and Non-convulsive), up to Visit 12","description":"Here, study visits followed by \"R\" indicate the Open-label Treatment Period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.22","spread":"7.289"},{"groupId":"OG001","value":"7.50","spread":"6.626"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.52","spread":"7.054"},{"groupId":"OG001","value":"6.08","spread":"5.932"}]}]}]},{"type":"SECONDARY","title":"Number of Separate Episodes of Status Epilepticus Up to Visit 12","description":"Here, study visits followed by \"R\" indicate the Open-label Treatment Period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.50"},{"groupId":"OG001","value":"1.4","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"2.17"},{"groupId":"OG001","value":"1.0","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a New Diagnosis of Epilepsy After Visit 11","description":"Here, study visits followed by \"R\" indicate the Open-label Treatment Period.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":65},"commonTop":["Pyrexia","Urinary tract infection","Pneumonia","Pleural effusion","Hypokalaemia"]}}}